These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 154923)

  • 1. Primary soluble plasmic degradation product of human cross-linked fibrin. Isolation and stoichiometry of the (DD)E complex.
    Olexa SA; Budzynski AZ
    Biochemistry; 1979 Mar; 18(6):991-5. PubMed ID: 154923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding phenomena of isolated unique plasmic degradation products of human cross-linked fibrin.
    Olexa SA; Budzynski AZ
    J Biol Chem; 1979 Jun; 254(11):4925-32. PubMed ID: 155698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of high molecular weight plasmic degradation products of human crosslinked fibrin.
    Olexa SA; Budzynski AZ; Marder VJ
    Biochim Biophys Acta; 1979 Jan; 576(1):39-50. PubMed ID: 153766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interference of plasmic degradation products of human crosslinked fibrin with clot formation.
    Budzynski AZ; Olexa SA; Brizuela BS
    Biochim Biophys Acta; 1979 May; 584(2):284-7. PubMed ID: 35237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of fibrinopeptide cleavage on the plasmic degradation pathways of human cross-linked fibrin.
    Olexa SA; Budzynski AZ
    Biochemistry; 1980 Feb; 19(4):647-51. PubMed ID: 6444516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complex-formation between the fibrin-derived plasmic fragments DD and E demonstrated by crossed immunoelectrophoresis.
    Gogstad GO; Brosstad F
    Thromb Res; 1983 Jun; 30(5):441-8. PubMed ID: 6225217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure.
    Francis CW; Marder VJ; Barlow GH
    J Clin Invest; 1980 Nov; 66(5):1033-43. PubMed ID: 6448866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A re-examination of the cleavage of fibrinogen and fibrin by plasmin.
    Ferguson EW; Fretto LJ; McKee PA
    J Biol Chem; 1975 Sep; 250(18):7210-8. PubMed ID: 126232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble high-molecular-weight E fragments in the plasmin-induced degradation products of cross-linked human fibrin.
    Gaffney PJ; Lane DA; Brasher M
    Clin Sci Mol Med; 1975 Aug; 49(2):149-56. PubMed ID: 125178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmin degradation of cross-linked fibrin.
    Marder VJ; Francis CW
    Ann N Y Acad Sci; 1983 Jun; 408():397-406. PubMed ID: 6223558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
    Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
    Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between complementary polymerization sites in the structural D and E domains of human fibrin.
    Ugarova TP; Budzynski AZ
    J Biol Chem; 1992 Jul; 267(19):13687-93. PubMed ID: 1618867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of fragment E species from human cross-linked fibrin.
    Olexa SA; Budzynski AZ; Doolittle RF; Cottrell BA; Greene TC
    Biochemistry; 1981 Oct; 20(21):6139-45. PubMed ID: 6458323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the physicochemical properties of fragment D derivatives of fibrinogen and fragment D-D of cross-linked fibrin.
    Marder VJ; Budzynski AZ; Barlow GH
    Biochim Biophys Acta; 1976 Mar; 427(1):1-14. PubMed ID: 130927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degradation of cross-linked fibrin by human leukocyte proteases.
    Francis CW; Marder VJ
    J Lab Clin Med; 1986 Apr; 107(4):342-52. PubMed ID: 3514776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of fragment E from fibrinogen and cross-linked fibrin.
    Slade CL; Pizzo SV; Taylor LM; Steinman HM; McKee PA
    J Biol Chem; 1976 Mar; 251(6):1591-6. PubMed ID: 815259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of primary polymerization sites in the D domain of human fibrinogen depends on intact conformation.
    Cierniewski CS; Kloczewiak M; Budzynski AZ
    J Biol Chem; 1986 Jul; 261(20):9116-21. PubMed ID: 3722190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding properties of 111In-diethylenetriaminepentaacetic acid (DTPA)-fragment E1,2, a fibrin-specific probe, are dependent on use of protecting complex during attachment of DTPA groups.
    Knight LC; Kollmann M; Maurer AH; Budzynski AZ
    Biochim Biophys Acta; 1987 Apr; 924(1):45-53. PubMed ID: 2950931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive exposure of E-neoantigen associated with degradation of crosslinked fibrin by plasmin in vitro.
    Stegnar M; Chen JP
    Thromb Haemost; 1984 Dec; 52(3):315-20. PubMed ID: 6241755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmic degradation of crosslinked fibrin. I. Structural analysis of the particulate clot and identification of new macromolecular-soluble complexes.
    Francis CW; Marder VJ; Martin SE
    Blood; 1980 Sep; 56(3):456-64. PubMed ID: 6447526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.